NCT06445803 - CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent

Interventions

BIOLOGICAL

KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）

"CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)"

Trial Locations (2)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

360000

RECRUITING

The First Affiliated Hospital of Nanchang University;, Nanchang